Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety study of sitaxsentan alone and sitaxsentan + sildenafil in pulmonary arterial hypertension
2008-005886-78Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of sitaxsentan and sildenafil in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Pfizer. Primary endpoint: Long-term safety of sitaxsentan and sitaxsentan plus sildenafil. Started Dec 2008; status: terminated.
02
Drugs
sitaxsentansildenafil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2008-005886-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005886-78.